RESUMEN
Human adenovirus infection (HAdV) may be fatal in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Cidofovir is effective in only a part of the post-HCT HAdV infection. Therefore, posttransplant immune reconstitution is important for HAdV clearance. We describe the detailed immune reconstitution and response of adenovirus-specific T cells in a patient with inborn errors of immunity who had disseminated HAdV infection with hepatitis post-HCT and was treated with cidofovir. Though the patient received cidofovir for only 19 days starting from Day 72 after HCT because of renal dysfunction, we observed T-cell reconstitution, a decrease in HAdV copy number, and amelioration of the symptoms of HAdV infection after Day 90. We initially observed expanded NK and CD8+CD45RO+ memory subsets and later gradual increase of naïve T cells eveloped after cessation of cidofovir treatment. An increase in adenovirus-specific IFN-γ secretion from 2 to 4 months after HCT was confirmed by ELISpot assay. The progression of immune reconstitution and cidofovir treatment are considered to have contributed to survival in this patient. Optimization of transplantation methods, prompt appropriate antiviral medication, and virus-specific T-cell therapy would be necessary as the better strategy for systemic HAdV infection.
Asunto(s)
Infecciones por Adenovirus Humanos , Antivirales , Cidofovir , Citosina , Trasplante de Células Madre Hematopoyéticas , Reconstitución Inmune , Organofosfonatos , Humanos , Cidofovir/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Organofosfonatos/uso terapéutico , Citosina/análogos & derivados , Citosina/uso terapéutico , Infecciones por Adenovirus Humanos/tratamiento farmacológico , Infecciones por Adenovirus Humanos/inmunología , Infecciones por Adenovirus Humanos/terapia , Antivirales/uso terapéutico , Trasplante Homólogo , Adenovirus Humanos/inmunología , Masculino , Hepatitis Viral Humana/tratamiento farmacológico , Hepatitis Viral Humana/inmunologíaAsunto(s)
Índice de Severidad de la Enfermedad , Humanos , Enfermedad Aguda , Niño , Masculino , Femenino , Preescolar , Hepatitis/inmunología , Hepatitis/virología , Hepatitis/etiología , Hepatitis/diagnóstico , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/virología , Hepatitis Viral Humana/diagnóstico , AdolescenteRESUMEN
Researchers scramble for data on the cause-and therefore the treatment-of liver disease in children.
Asunto(s)
Infecciones por Adenoviridae , Adenoviridae , COVID-19 , Hepatitis Viral Humana , SARS-CoV-2 , Adenoviridae/aislamiento & purificación , Infecciones por Adenoviridae/complicaciones , COVID-19/complicaciones , Niño , Hepatitis Viral Humana/tratamiento farmacológico , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/virología , HumanosRESUMEN
In chronic viral hepatitis and in hepatocarcinoma (HCC), antigen-specific T cells are deeply exhausted, and evidence of dysfunction has also been observed for NK cells, which can play a pathogenetic role, exerting a regulatory activity on adaptive immune responses [...].
Asunto(s)
Carcinoma Hepatocelular/inmunología , Carcinoma Hepatocelular/terapia , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/terapia , Inmunoterapia , Células Asesinas Naturales/inmunología , Neoplasias Hepáticas/terapia , Linfocitos T/inmunología , Enfermedad Crónica , Citocinas/metabolismo , Humanos , Neoplasias Hepáticas/inmunología , Linfocitos Infiltrantes de Tumor/inmunologíaRESUMEN
BACKGROUND: Covid-19 has the respiratory tract as the main target of infection, and patients present mainly dyspnea, pneumonia, dry cough, and fever. Nevertheless, organs outside the respiratory tract had been reported in recent studies, including the gastrointestinal tract and liver. The host innate immune system recognizes pathogen-associated molecular patterns (PAMPs) through their pattern recognition receptor (PRRs). Toll-like receptor 7 (TLR-7) is a pattern recognition receptor recognizing ssRNA (SARS-CoV-2 is an ssRNA). Polymorphisms are characterized by two or more alternative forms of a distinct phenotype in the same population. Polymorphisms in tlrs genes can negatively influence the immune response to infectious diseases. There are several references in the literature to non-synonymous single nucleotide (rs) polymorphisms related to several genes. Some of them are important for the innate immunity, as rs 179008 (tlr-7), rs3775291 (tlr3), rs8177374 (tir domain-containing adaptor protein, tirap), rs1024611 (monocyte chemoattractant protein-1, mcp-1) and rs61942233 (2'-5'-oligoadenylate synthase-3, oas-3). CASE PRESENTATION: We identified a 5-year-old-male child with gastrointestinal symptoms and fever presenting acholic stool and jaundice, who was positive for SARS-CoV-2 IgM, IgA, and IgG and presenting the Gln11Leu rs 179008 in tlr-7. The child presented high levels of aspartate aminotransferase, alanine aminotransferase, bilirubin, C-reactive protein, D-dimer, gamma-glutamyl transferase, alkaline phosphatase, and was negative for serological tests for hepatitis A, B, C, E, HIV 1 and 2, herpes virus, cytomegalovirus, Epstein-Barr virus, and negative for RTqPCR for Influenza A and B, RSV and SARS-CoV-2. We also investigated other SNPs in the tlr-3 (rs3775291), tirap (rs8177374), mcp-1 (rs1024611), and oas-3 (rs61942233) genes, and no mutation was detected. After an interview with the child's caregivers, any possible accidental ingestion of drugs or hepatotoxic substances was ruled out. CONCLUSION: To our knowledge, this is the first report of a SARS-CoV-2 caused hepatitis in a male child that has the tlr-7 Gln11Leu rs 179008, which could impair an efficient initial immune response. The knowledge of the patient's immune deficiency could improve the treatment to correct this deficiency with specific medications.
Asunto(s)
COVID-19/genética , COVID-19/virología , Hepatitis Viral Humana/genética , Hepatitis Viral Humana/virología , Receptor Toll-Like 7/genética , Anticuerpos Antivirales/sangre , COVID-19/inmunología , Preescolar , Infecciones por Virus de Epstein-Barr/genética , Infecciones por Virus de Epstein-Barr/virología , Heces/virología , Hepatitis Viral Humana/inmunología , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Inmunidad Innata , Gripe Humana , Masculino , Polimorfismo de Nucleótido Simple , SARS-CoV-2/aislamiento & purificaciónRESUMEN
Natural killer (NK) cells account for 25-50% of the total number of hepatic lymphocytes, which implicates that NK cells play an important role in liver immunity. The frequencies of both circulating and tumor infiltrating NK cells are positively correlated with survival benefit in hepatocellular cancer (HCC) and have prognostic implications, which suggests that functional impairment in NK cells and HCC progression are strongly associated. In HCC, T cell exhaustion is accompanied by the interaction between immune checkpoint ligands and their receptors on tumor cells and antigen presenting cells (APC). Immune checkpoint inhibitors (ICIs) have been shown to interfere with this interaction and have altered the therapeutic landscape of multiple cancer types including HCC. Immunotherapy with check-point inhibitors, aimed at rescuing T-cells from exhaustion, has been applied as first-line therapy for HCC. NK cells are the first line effectors in viral hepatitis and play an important role by directly eliminating virus infected cells or by activating antigen specific T cells through IFN-γ production. Furthermore, chimeric antigen receptor (CAR)-engineered NK cells and T cells offer unique opportunities to create CAR-NK with multiple specificities learning from the experience gained with CAR-T cells with potentially less adverse effects. This review focus on the abnormalities of NK cells, T cells, and their functional impairment in patients with chronic viral hepatitis, which contributes to progression to hepatic malignancy. Furthermore, we discuss and summarize recent advances in the NK cell and T cell based immunotherapeutic approaches in HCC.
Asunto(s)
Carcinoma Hepatocelular , Hepatitis Viral Humana , Inmunoterapia/métodos , Células Asesinas Naturales/inmunología , Neoplasias Hepáticas , Linfocitos T/inmunología , Animales , Carcinoma Hepatocelular/inmunología , Carcinoma Hepatocelular/terapia , Línea Celular , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/terapia , Humanos , Células Asesinas Naturales/citología , Neoplasias Hepáticas/inmunología , Neoplasias Hepáticas/terapia , Linfocitos T/citologíaRESUMEN
More patients with chronic hepatitis B and C infection are being exposed to immune checkpoint inhibitors (ICIs), but the safety and efficacy of ICIs in patients with chronic viral hepatitis are still poorly described. To explore this interaction, we identified eight studies of cancer patients with viral hepatitis treated with one or more ICIs, formally assessed tumor responses and safety by grading liver dysfunction. ICIs appear to be relatively safe in HBV/HCV-infected patients, and hepatitis related to viral reactivation is rare. In some patients, viral load regressed during ICI treatment, so immune checkpoints may play a role in viral clearance. HBV/HCV do not appear to be a contraindication to ICIs, although careful clinical and biochemical follow-up is recommended and, whenever necessary, antiviral therapy commenced.
Asunto(s)
Hepatitis Viral Humana/tratamiento farmacológico , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Neoplasias/tratamiento farmacológico , Enfermedad Crónica , Hepacivirus/efectos de los fármacos , Hepacivirus/fisiología , Virus de la Hepatitis B/efectos de los fármacos , Virus de la Hepatitis B/fisiología , Hepatitis Viral Humana/complicaciones , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/virología , Humanos , Hígado/efectos de los fármacos , Hígado/inmunología , Neoplasias/complicaciones , Neoplasias/inmunología , Neoplasias/virología , Literatura de Revisión como Asunto , Carga Viral/efectos de los fármacos , Activación Viral/efectos de los fármacosRESUMEN
Viral hepatitis is a deadly disease which can manifest as acute, chronic, hepatocellular carcinoma, and liver failure. Information about hepatitis is scarce among animal handlers. Due to Federal Government of Nigeria diversification programmes, many people are now involved in animal farming which can make them susceptible to viral hepatitis. This study aimed at determining the prevalence of Hepatitis B, C, and E viruses among animal handlers in Abeokuta, southwestern Nigerian. A total of 156 subjects were recruited for the study. Sociodemographic and risks factors data were fetched from subjects using interviewer-administered questionnaire. Blood samples were collected via venepuncture and tested for HCV, HBV, and HEV using ELISA technique. Results were analyzed using SPSS software version 21.0 and P value ≤ 0.05 was considered significant. The prevalence of HCV, HBV, and HEV were 46 (29.5%), 20 (12.8%), and 4 (2.6%) respectively while 6 (3.8%), 1 (0.6%), and 1 (0.6%) had co-infection of HBV-HCV, HBV-HEV, and HCV- HEV respectively. This study concludes that there is high prevalence of hepatitis C and B viruses among animal handlers in Abeokuta, Ogun state which is of significant public health problem, warranting further attention and research.
Asunto(s)
Hepatitis B/inmunología , Hepatitis C/inmunología , Hepatitis E/inmunología , Hepatitis Viral Humana/inmunología , Adulto , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepatitis B/epidemiología , Hepatitis B/virología , Hepatitis C/epidemiología , Hepatitis C/virología , Hepatitis E/epidemiología , Hepatitis E/virología , Hepatitis Viral Humana/epidemiología , Hepatitis Viral Humana/virología , Humanos , Masculino , Persona de Mediana Edad , Nigeria/epidemiología , Estudios Seroepidemiológicos , Adulto JovenRESUMEN
A previously well and immunocompetent 64-year-old woman presented with fever of unknown origin and acute hepatitis. Besides headache and nausea, she had no other symptoms. Her clinical examination was unremarkable with no clear focus of infection. She was thoroughly investigated and her biochemical profile suggested a viral or autoimmune aetiology. Multiple imaging modalities gave no further insight. Her serology and subsequent nucleic acid amplification indicated reactivation of latent cytomegalovirus (CMV). Her symptoms resolved with supportive care and no anti-viral therapy was needed. This case report highlights CMV reactivation leading to acute hepatitis in a well, immunocompetent patient.
Asunto(s)
Infecciones por Citomegalovirus/complicaciones , Hepatitis Viral Humana/etiología , Inmunocompetencia , Enfermedad Aguda , Anticuerpos Antivirales/sangre , Citomegalovirus , Infecciones por Citomegalovirus/inmunología , Femenino , Hepatitis Viral Humana/diagnóstico , Hepatitis Viral Humana/inmunología , Humanos , Persona de Mediana EdadRESUMEN
BACKGROUND: The capacity to integrate platforms across vendors and disciplines has become an essential feature in the design of total laboratory automation (TLA) due space and test menu constraints. However, data on its performance are lacking. We aim to evaluate an integrated third-party immunoassay platform to the TLA system for the performance of hepatitis testing using turnaround time (TAT). METHODS: We use the Beckman Power Express (PE) system with linked 2 Beckman AU5800, 2 Beckman DxI 800, 2 Abbott Architect i2000, and other accessory components. The PE system is managed and interfaced to the laboratory information system (LIS) through Beckman Remisol (middleware) and Cennexus (track software). The hepatitis tests are performed on the Abbott Architect i2000 using Abbott Instrument Manager (middleware) for test results and this is interfaced with LIS and Cennexus. Using Viewics and Microsoft Excel, the test volumes and TAT of hepatitis results were analyzed before (February 2017 to January 2018) and after (February 2018 to January 2019) integration. RESULTS: The TAT for each hepatitis test has decreased significantly, ranging from 13 to 81-minute reductions (P value <0.0001 for all tests) after instrument integration. The standard deviations of the TAT also decreased for each test. In addition, savings in labor expenditure of around 2 hours per day were observed. There were no laboratory space savings identified. Instead, 47.6 square foot more of space was utilized by the track connection lines. CONCLUSIONS: Our findings show significant improvement of TAT of hepatitis testing with the integration of the third-party Abbott Architect i2000 to Beckman PE system. In addition, the synchronization of multiple middleware for specimen management and result reporting allow the laboratory to achieve new efficiencies handling reflex tests and managing human resources.
Asunto(s)
Automatización de Laboratorios/instrumentación , Anticuerpos Antihepatitis/sangre , Virus de Hepatitis/inmunología , Hepatitis Viral Humana/diagnóstico , Pruebas Serológicas/instrumentación , Anticuerpos Antihepatitis/inmunología , Hepatitis Viral Humana/sangre , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/virología , Humanos , Pruebas Serológicas/métodos , Programas InformáticosRESUMEN
Chronic infection with viral hepatitis is a major risk factor for liver injury and hepatocellular carcinoma (HCC). One major contributing factor to the chronicity is the dysfunction of virus-specific T cell immunity. T cells engineered to express virus-specific T cell receptors (TCRs) may be a therapeutic option to improve host antiviral responses and have demonstrated clinical success against virus-associated tumours. This review aims to give an overview of TCRs identified from viral hepatitis research and discuss how translational lessons learned from cancer immunotherapy can be applied to the field. TCR isolation pipelines, liver homing signals, cell type options, as well as safety considerations will be discussed herein.
Asunto(s)
Hepatitis Viral Humana/inmunología , Receptores de Antígenos de Linfocitos T/genética , Linfocitos T/inmunología , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/terapia , Humanos , Inmunoterapia/métodos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/terapia , Receptores de Antígenos de Linfocitos T/inmunología , Receptores de Antígenos de Linfocitos T/metabolismoRESUMEN
In rare cases, hepatitis A virus (HAV) and hepatitis B virus (HBV) can cause fulminant viral hepatitis (FVH), characterized by massive hepatocyte necrosis and an inflammatory infiltrate. Other viral etiologies of FVH are rarer. FVH is life-threatening, but the patients are typically otherwise healthy, and normally resistant to other microbes. Only a small minority of infected individuals develop FVH, and this is the key issue to be addressed for this disease. In mice, mouse hepatitis virus 3 (MHV3) infection is the main model for dissecting FVH pathogenesis. Susceptibility to MHV3 differs between genetic backgrounds, with high and low mortality in C57BL6 and A/J mice, respectively. FVH pathogenesis in mice is related to uncontrolled inflammation and fibrinogen deposition. In humans, FVH is typically sporadic, but rare familial forms also exist, suggesting that there may be causal monogenic inborn errors. A recent study reported a single-gene inborn error of human immunity underlying FVH. A patient with autosomal recessive complete IL-18BP deficiency was shown to have FVH following HAV infection. The mechanism probably involves enhanced IL-18- and IFN-γ-dependent killing of hepatocytes by NK and CD8 T cytotoxic cells. Proof-of-principle that FVH can be genetic is important clinically, for the affected patients and their families, and immunologically, for the study of immunity to viruses in the liver. Moreover, the FVH-causing IL18BP genotype suggests that excessive IL-18 immunity may be a general mechanism underlying FVH, perhaps through the enhancement of IFN-γ immunity.
Asunto(s)
Citocinas/inmunología , Hepadnaviridae/genética , Hepatitis Viral Humana/genética , Hepatitis Viral Humana/patología , Hepadnaviridae/patogenicidad , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/virología , HumanosRESUMEN
Liver cancer is the third most common cause of cancer related death in the World. From an epidemiological point of view the risk factors associated to primary liver cancer are mainly viral hepatitis infection and alcohol consumption. Even though there is a clear correlation between liver inflammation, cirrhosis and cancer, other emerging liver diseases (like fatty liver) could also lead to liver cancer. Moreover, the liver is the major site of metastasis from colon, breast, ovarian and other cancers. In this review we will address the peculiar status of the liver as organ that has to balance between tolerance and immune activation. We will focus on macrophages and other key cellular components of the liver microenvironment that play a central role during tumor progression. We will also discuss how current and future therapies may affect the balance toward immune activation.
Asunto(s)
Tolerancia Inmunológica/inmunología , Neoplasias Hepáticas/inmunología , Hígado/inmunología , Animales , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/patología , Humanos , Hígado/patología , Neoplasias Hepáticas/patologíaRESUMEN
Disseminated herpes simplex virus (HSV) is mainly seen in immunocompromised individuals. Atypical lesions can be present in both primary infection and reactivation disease. Compared with the general population, inmunocompromised hosts are at greater risk of increased persistency and severity of clinical manifestations, including severe systemic involvement such as esophagitis, meningitis, and hepatitis. Herein, we report the case of a liver transplant recipient with atypical disseminated herpes simplex virus-1 complicated by HSV-related hepatitis. Dermatological consultation and histological assessment were crucial for a correct diagnosis and treatment.
Asunto(s)
Hepatitis Viral Humana/virología , Herpes Simple/patología , Herpesvirus Humano 1/aislamiento & purificación , Huésped Inmunocomprometido , Piel/patología , Anticuerpos Antivirales/sangre , Hepatitis Viral Humana/inmunología , Herpesvirus Humano 1/inmunología , Humanos , Trasplante de Hígado , Masculino , Persona de Mediana EdadRESUMEN
The liver is primarily thought of as a metabolic organ; however, the liver is also an important mediator of immunological functions. Key perspectives on this emerging topic were presented in a symposium at the 2018 annual meeting of the American College of Toxicology entitled "Beyond metabolism: Role of the immune system in hepatic toxicity." Viral hepatitis is an important disease of the liver for which insufficient preventive vaccines exist. Host immune responses inadequately clear these viruses and often potentiate immunological inflammation that damages the liver. In addition, the liver is a key innate immune organ against bacterial infection. Hepatocytes and immune cells cooperatively control systemic and local bacterial infections. Conversely, bacterial infection can activate multiple types of immune cells and pathways to cause hepatocyte damage and liver injury. Finally, the immune system and specifically cytokines and drugs can interact in idiosyncratic drug-induced liver injury. This rare disease can result in a disease spectrum that ranges from mild to acute liver failure. The immune system plays a role in this disease spectrum.
Asunto(s)
Infecciones Bacterianas/inmunología , Enfermedad Hepática Inducida por Sustancias y Drogas/inmunología , Hepatitis Viral Humana/inmunología , Hígado/inmunología , Animales , Citocinas/inmunología , Humanos , Hígado/microbiología , Hígado/virologíaRESUMEN
BACKGROUND: Interleukin (IL)-35 is a newly indentified cytokine and induces immunotolerance via suppression of CD8+ T cell activity in chronic viral hepatitis. AIMS: To investigate the modulatory function of IL-35 to CD8+ T cells in viral hepatitis-induced acute-on-chronic liver failure (ACLF). METHODS: Fifty-five ACLF patients and 21 healthy controls were enrolled. Serum IL-35 concentration was measured by ELISA. Absolute accounts for T cells, immune checkpoint molecules, and cytotoxic molecules in CD8+ T cells were measured by flow cytometry and real-time PCR, respectively. Direct and indirect contact co-culture systems between CD8+ T cells and HepG2 cells were set up. The regulatory function of IL-35 to CD8+ T cells was assessed by measuring lactate dehydrogenase expression and cytokine production. RESULTS: Serum IL-35 concentration was elevated in ACLF patients and positively correlated with total bilirubin, but negatively correlated with prothrombin time activity. Peripheral CD8+ T cells showed exhausted phenotype in ACLF patients, which manifested as up-regulation of programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3) but down-regulation of perforin, granzyme B, and FasL. Recombinant IL-35 stimulation dampened cytotoxicity and interferon-γ production in both direct and indirect contact co-culture systems. This process was accompanied by elevation of PD-1, CTLA-4, and LAG3, as well as reduction of perforin, granzyme B, and FasL in CD8+ T cells. CONCLUSION: Elevated IL-35 suppressed both cytolytic and non-cytolytic activity of CD8+ T cells in ACLF patients.
Asunto(s)
Insuficiencia Hepática Crónica Agudizada , Linfocitos T CD8-positivos/inmunología , Hepatitis Viral Humana , Tolerancia Inmunológica , Interleucinas , Activación de Linfocitos/inmunología , Insuficiencia Hepática Crónica Agudizada/sangre , Insuficiencia Hepática Crónica Agudizada/inmunología , Bilirrubina/sangre , Técnicas de Cocultivo/métodos , Pruebas Inmunológicas de Citotoxicidad/métodos , Femenino , Células Hep G2 , Hepatitis Viral Humana/sangre , Hepatitis Viral Humana/inmunología , Humanos , Interleucinas/sangre , Interleucinas/inmunología , Masculino , Persona de Mediana Edad , Tiempo de Protrombina/métodos , Proteínas Recombinantes/sangre , Proteínas Recombinantes/inmunologíaRESUMEN
Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.
Asunto(s)
Acetatos/administración & dosificación , Antivirales/administración & dosificación , Infecciones por Citomegalovirus/tratamiento farmacológico , Citomegalovirus , Monitoreo de Drogas/métodos , Huésped Inmunocomprometido , Neumonía Viral/tratamiento farmacológico , Quinazolinas/administración & dosificación , Acetatos/farmacocinética , Acetatos/uso terapéutico , Antivirales/farmacocinética , Antivirales/uso terapéutico , Preescolar , Ensayos de Uso Compasivo , Citomegalovirus/genética , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/inmunología , Infecciones por Citomegalovirus/virología , ADN Viral/sangre , Relación Dosis-Respuesta a Droga , Oxigenación por Membrana Extracorpórea/efectos adversos , Resultado Fatal , Femenino , Ganciclovir/uso terapéutico , Hepatitis Viral Humana/tratamiento farmacológico , Hepatitis Viral Humana/inmunología , Humanos , Infecciones Oportunistas/tratamiento farmacológico , Neumonía Viral/inmunología , Neumonía Viral/virología , Reacción en Cadena de la Polimerasa , Quinazolinas/farmacocinética , Quinazolinas/uso terapéutico , Insuficiencia del Tratamiento , Carga ViralRESUMEN
BACKGROUND: Viral hepatitis is a global public health problem affecting millions of people worldwide, causing thousands of deaths due to acute and persistent infection, cirrhosis, and liver cancer. Providing updated serologic data can improve both surveillance and disease control programs. This study is aimed to determine the seroprevalence of markers for viral hepatitis (A, B, C, D and E) and the epidemiology of such infections in the general population of southern Iran's Hormozgan province. METHODS: Between 2016 and 2017, a total of 562 individuals with ages ranging from 1 to 86 years, who visited governmental public laboratories for routine check-ups, were tested for the presence of serological markers to hepatitis virus types A to E using enzyme-linked immunosorbent assays. RESULTS: The overall anti-hepatitis A virus (HAV) antibody seroprevalence was 93.2% (524/562). The prevalence of anti-hepatitis E virus (HEV) antibodies was 15.8% (89/562) among which 1.6% (9/562) of the seropositive individuals also had evidence of recent exposure to the virus (IgM positivity). Two and a half percent (14/562) were positive for hepatitis B surface (HBs) antigen, whereas 11.6% (65/562) tested positive for anti-hepatitis B core (HBc) antibodies. Among anti-HBc positive patients, 11% (7/65) had HBs Ag and 5% (3/65) were positive for anti-hepatitis D virus (HDV) antibodies. The prevalence of anti-hepatitis C virus (HCV) antibodies was 0.7% (4/562). The seroprevalence of anti-HAV, HEV IgG, anti-HBc antibodies, and HBs Ag increased with age. CONCLUSION: The present study confirms a high seroprevalence of HAV infection among the examined population and reveals high levels of endemicity for HEV in the region. Planned vaccination policies against HAV should be considered in all parts of Iran. In addition, improvements on public sanitation and hygiene management of drinking water sources for the studied area are recommended.
Asunto(s)
Hepatitis Viral Humana/epidemiología , Hepatitis Viral Humana/inmunología , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Niño , Preescolar , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Anticuerpos Antihepatitis/sangre , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/inmunología , Virus de Hepatitis/inmunología , Hepatitis Viral Humana/prevención & control , Humanos , Lactante , Irán/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Seroepidemiológicos , Vacunación , Adulto JovenRESUMEN
BACKGROUND: Prison inmates are considered a high-risk population for blood-borne and enterically transmitted infections before and during their imprisonment. Hepatitis E virus (HEV) prevalence is unknown among French inmates, whereas a reassessment of human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) prevalences is required to describe the epidemiologic evolution in this high-risk population. METHODS: A prospective survey was conducted from June to December 2017 in Fresnes prison, a penitentiary center with 2,581 inmates. In addition to HIV, HAV, HBV and HCV testing, which is offered to all patients at admission, we systematically offered HEV screening. Retrospective serological data for HIV, HBV and HCV, collected annually from 2014 to 2017, were also used to assess evolution. RESULTS: In 2017, 1,093 inmates were screened for HEV, HIV, HAV, HBV and HCV. Prevalences in this population were 8.2%, 1.3%, 62.7%, 1.9% and 2.9%, respectively. HEV seroprevalence increased with age (p<0.0001) and was higher among Eastern Europe born inmates (p<0.0001). Between 2014 and 2017, HIV seroprevalence remained steady, while a decrease in HBV and HCV seroprevalence was observed. CONCLUSIONS: Compared to the reported prevalence in French blood donors, HEV seroprevalence was remarkably low in French inmates. HIV, HAV, HBV and HCV prevalences among prisoners were higher than reported in the general population.